ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALLR Allarity Therapeutics Inc

1.49
0.22 (17.32%)
May 01 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Allarity Therapeutics Inc ALLR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.22 17.32% 1.49 18:59:59
Open Price Low Price High Price Close Price Previous Close
1.27 1.15 1.44 1.37 1.27
more quote information »

Recent News

Date Time Source Heading
4/29/202406:00GLOBEAllarity Therapeutics Regains Compliance with NASDAQ Minimum..
4/17/202408:10GLOBEAllarity Therapeutics Receives NASDAQ-Approved Extension to..
4/04/202408:15GLOBEAllarity Therapeutics Announces 1-for-20 Reverse Stock Split
3/27/202407:30GLOBEAllarity Therapeutics Makes Strategic Pivot to Focus Solely..
3/25/202406:30GLOBEAllarity Therapeutics Receives Extension from Nasdaq..
3/08/202407:38EDGAR2Form 8-K - Current report
3/08/202406:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/08/202406:15GLOBEAllarity Therapeutics Reports Full Year 2023 Financial..
3/07/202420:45EDGAR2Form DEF 14A - Other definitive proxy statements
3/04/202415:05EDGAR2Form 8-K - Current report
3/01/202408:21EDGAR2Form 8-K - Current report
2/28/202405:00GLOBEAllarity Therapeutics to Present at Biomarkers 2024
2/23/202415:09EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
2/14/202408:03EDGAR2Form 8-K - Current report
2/02/202416:03EDGAR2Form D - Notice of Exempt Offering of Securities
2/01/202415:40EDGAR2Form 8-K - Current report
1/26/202416:07EDGAR2Form PRE 14A - Other preliminary proxy statements
1/25/202416:24EDGAR2Form 8-K - Current report
1/19/202416:29EDGAR2Form 8-K - Current report
12/15/202316:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202305:00GLOBEAllarity Therapeutics Announces Thomas Jensen as Interim CEO..
12/11/202305:30EDGAR2Form 8-K - Current report
12/06/202316:00EDGAR2Form 8-K - Current report
12/06/202307:30EDGAR2Form S-1/A - General form for registration of securities..
12/05/202306:30EDGAR2Form 8-K - Current report
12/05/202306:30GLOBEAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
11/17/202316:01EDGAR2Form 8-K - Current report
11/13/202307:35EDGAR2Form 8-K - Current report
11/02/202316:00EDGAR2Form S-3 - Registration statement under Securities Act of..
10/31/202308:30EDGAR2Form S-1 - General form for registration of securities under..
10/30/202316:00EDGAR2Form 8-K - Current report
10/23/202316:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/17/202316:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
10/10/202316:00EDGAR2Form S-3 - Registration statement under Securities Act of..
10/02/202306:00GLOBEAllarity Therapeutics to Present at Biomarkers Europe 2023
9/27/202315:30EDGAR2Form 8-K - Current report
9/15/202307:45EDGAR2Form 8-K - Current report
8/30/202315:05GLOBEPLOS ONE Publishes Data on Allarity Therapeutics’ DRP®..
8/14/202314:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/11/202307:15EDGAR2Form 8-K - Current report
7/31/202305:00GLOBEAllarity Therapeutics and FivepHusion Announce Collaboration..
7/27/202315:01EDGAR2Form 8-K - Current report
7/24/202305:00GLOBEAllarity Therapeutics Strengthens Board of Directors with..
7/17/202316:10EDGAR2Form 8-K - Current report
7/11/202315:05EDGAR2Form 8-K - Current report
7/07/202315:30EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
7/06/202305:05EDGAR2Form 8-K - Current report
7/06/202305:00GLOBEAllarity Therapeutics, Inc. Announces Pricing of $11 Million..
7/05/202315:31EDGAR2Form 8-K - Current report
7/05/202308:45GLOBEInitial Data from Allarity’s Phase 2 Trial of IXEMPRA®..

Your Recent History

Delayed Upgrade Clock